Most Common Side Effects of Kisqali
Kisqali (ribociclib), used to treat HR+/HER2- advanced breast cancer, frequently causes low white blood cell counts (neutropenia, 74-80% of patients), fatigue (41-71%), nausea (29-52%), hair thinning or loss (33-51%), vomiting (29-46%), diarrhea (21-35%), and hair loss (33%). These often occur early in treatment and may require dose adjustments.[1][2]
How Side Effects Are Managed
Neutropenia is monitored via regular blood tests; doctors may pause or reduce doses if counts drop too low. Nausea and vomiting are typically handled with anti-nausea drugs like ondansetron. Fatigue improves with rest and light activity. Hair thinning is usually temporary and reversible after stopping treatment.[1][3]
Serious Side Effects Patients Should Watch For
Less common but serious risks include severe infections from low white blood cells (10-15%), liver problems (elevated enzymes in 10-18%), lung inflammation (interstitial lung disease, <1% but potentially fatal), heart rhythm changes (QT prolongation, 1-3%), and low platelets (thrombocytopenia, 1-24%). Seek immediate care for fever, shortness of breath, yellowing skin, or irregular heartbeat.[1][2]
Side Effects by Treatment Cycle
Most effects peak in the first two 28-day cycles, with neutropenia hitting hardest around days 7-14. Incidence drops after cycle 2 as bodies adjust. Long-term use sees ongoing low-grade fatigue and nausea in about 20-30% of patients.[2][3]
Kisqali vs. Similar Drugs Like Ibrance
Kisqali's neutropenia rate (74-80%) exceeds Ibrance (palbociclib, 60-70%), but it has lower diarrhea (21-35% vs. 25-40%). Both share fatigue and nausea profiles; Kisqali adds more hair thinning. Choice depends on patient tolerance and tumor response.[1][4]
Who Experiences Side Effects Most
Premenopausal women and those over 65 report higher rates of fatigue and neutropenia. Combining with hormone therapies like letrozole increases nausea by 10-15%. No major differences by race, but Asian patients see slightly elevated liver enzyme risks.[2]
[1]: Kisqali Prescribing Information (Novartis, FDA-approved label)
[2]: MONALEESA Trials (NEJM, Lancet Oncology)
[3]: NCCN Breast Cancer Guidelines (Version 5.2024)
[4]: Ibrance Prescribing Information (Pfizer)